48
46)
Hoekmank K, von Blomberg- van Der Flier BM, Wagstaff J, Drexhage HA, Pinedo
HM. Reversible thyroid dysfunction during treatment with GM-CSF. Lancet 1991; 338: 541-2.
47)
Atkins MB, Mier JW, Parkinson DR, Goul JA, Berkman EM, Kaplan MM.
Hypothyroidism after treatment with interleukin- 2 and lymphokine- activated killer cell. N
Eng J Med 1988; 318: 1557- 63.
48)
Limachi F, Basso S. Apoptosis: life trough planned cellular death regulating
mechanisms, control systems, and relations with thyroid disease. Thyroid 2002; 12. 27- 34.
49)
Doniach D. Hashimoto’s thyroiditis and primary myxedema viewed as separate entities.
Eur J Clin Invest 1981; 11: 245- 9.
50)
Brown J, Solomon DH, Beall GN. Autoimmune thyoid disease: Graves and
Hashimoto’s. Ann Intern Med 1978; 88: 379- 82.
51)
Ostrov DA, Shi W, Schwartz JC, Almo SC, Nathenson SG. Structure of murine CTLA-
4 and its role in modulating T cell responsiveness. Science 2000; 290: 816- 9.
52)
Ueda H, Howson JM, Esposito L. Association of the T- cell regulatory gene CTLA- 4
with susceptibility to autoimmune disease. Nature 2003; 423: 506- 511.
53)
Pearce SH, Cheetham T, Imrie H, Vaidya B, Barnes ND, Bilous RW, et al. A common
and recurrent 13-bp deletion in the autoimmune regulatory gene in British kindreds with
autoimmune polyendocrinopathy type I. Am J Hum Genet 1998; 63: 1675- 84.
54)
Yashida H, Amino N, Yagawa K, Uemura K, Satoh M, Miyai K, et al. Association of
serum antithyroid antibodies and lymphocytic infiltration of the thyroid gland: studies of 70
autopsied cases. J Clin Endocrinol Metab 1978; 46: 859- 62.
55)
Okamoto Y, Hamada N, Saito H, Ohno M, Noh J, Ito K, et al. Thyroid peroxidase
activity- inhibiting immunglobulins in patients with autoimmune thyroid disease. J Clin
Endocrinol Metab 1989; 68: 730- 4.
56)
Lorini R, Gastaldi R, Traggiai C, Perucchin PP, Hashimoto’s Thyroiditis. Pediatr
Endocrinol Rev 2003; 1 Suppl 2: 205- 11.
57)
Takasu N, Komiya I, Asawa T, Nagasawa Y, Yamada T. Test for recovery from
hypothyroidism during thyroxine therapy in Hashimoto’s thyroiditis. Lancet 1990; 336: 1084-
6.
58)
Baker JR Jr, Saunders NB, Wartofsky L, Tseng YC, Burman KD. Seronegative
Hashimoto’s thyroiditis with thyroid autoantibody production lokalized to the thyroid. Ann
Inter Med 1988; 108: 26- 30.
59)
Hueston WJ. Treatment of hypothyoidism. Am Fam Physician 2001; 64: 1717- 24.
49
60)
Pederson OM, Aordal NP, Larssen TB, Varhauq JE, Myking O, Vik-Mo H. The value
of ultrosonography in predicting autoimmune thyroid disease. Thyroid 2000; 10: 251- 9.
61)
Hegedüs L, Hansen JM, Feldt- Rasmussen U, Hansen BM, Hoier-Madsen M. Influence
of thyroxine treatment on thyroid size and antithyroid peroxidase antibodies in Hashimoto’s
thyroiditis. Clin Endocrinol (Oxf) 1991; 35: 235- 8.
62)
Svensson J, Ericsson UB, Nilsson P, Olsson C, Jonsson B, Lindberg B, et al.
Levothyroxine treatment reduce thyroid size in children and adolescents with chronic
autoimmune thyroiditis. J Clin Endocrinol Metab. 2006;91: 1729- 34.
63)
Wernly M, Courvosier and Fischer JA: The parathyroids: Clinical Endocrinology, ed
Labhart, Alexis, New York 1974.
64)
Nusynowitz ML, Klein MH. Pseudoidiopatic hypoparathyroidism with ineffective
parathyroid hormones. Am J Med 1973; 55: 677- 86.
65)
Habener JF, Potts JT. Relative effectiveness of magnesium and calsium in the control of
parathyroid hormone secretion and biosynthesis. Endocrinology 1976; 98: 209- 214.
66)
Buckle RM, Care AD, Cooper CW, Gitelman HJ. The influence of plasma magnesium
concentration on parathyroid hormone secretion. Journal of Endoc 1968; 42, 529- 34.
67)
Fucik RF, Kureja SC, Hargis GK, Bowser EN, Henderson WJ, Williams GA. Effect of
glucocorticoids on function of the parathyroid glands in man. J Clin Endocr Metab 1975; 40:
152- 5.
68)
Kayaalp O, Rasyonel tedavi yönünden tıbbi farmakoloji. Feryal matbaacılık 2002.
69)
Avila E, Barrera D, Diaz L. Calciotropic actions of parathyroid hormone and vitamin- D
endocrine system. Rev Invest Clin 2007; 59: 306- 17.
70)
Segre GV, Perkis AS, Witters LA, Potts J Jr. Metabolism of parathyroid hormone by
isolated rat kuppfer cells and hepatocytes. J of Clin Inves 1981; 67: 449- 57.
71)
Reeve J, Hesp R, Williams S, Hulme P, Klenerman L, Zanelli JM, et al. Anabolic effect
of low doses of human parathyroid hormone on the skeleton in postmenopausal osteoporosis.
Lancet 1976; 1: 1035- 8.
72)
Naveh- Many T, Epstein E, Silver J. Oestrogen and calcium regulatory hormones:
Potential implications for bone. Curr Opin Nephrol Hypertens.1995; 4(4): 319- 23.
73)
Root AW, Harrison HE. Recent advances in calcium metabolism. II. Disorders of
calcium homeostasis. J Pediatr 1976; 88: 177- 99.
74)
Barzel US. Parathyroid hormone, blood phosphorus and acid base metabolism. Lancet
1971; 1: 1329- 34.